Asset
Imdusiran Sodium
Arbutus Biopharma Corporation Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04980482 | phase2 | completed | 2021-10-29 | 2025-03-13 | Arbutus Biopharma Corporation | Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection |
FDA applications (0)
This company has no applications containing this asset.